As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to：www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global：
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China：
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
Based on their ability to activate GLP-1 receptor, GLP-1R agonists can be classified as short-acting and long-acting GLP-1R agonists. Short-acting GLP-1R agonists are require to give either a once-daily (QD) or twice-daily (BID) dosing (e.g., Exenatide and Lixisenatide). Long-acting GLP-1R agonists have undergone some structural modifications to enhance their duration of action, while retaining their ability to act on the GLP-1 receptors (e.g., Albiglutide, Dulaglutide, once weekly).
Medicilon provides GLP-1 drug discovery, CMC research (API + formulation), pharmacodynamics research, PK study, GLP-1 safety evaluation and other services.
Share：
Relevant news
marketing@medicilon.com
ABOUT
